Patents by Inventor Lemoine Nick

Lemoine Nick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED INTERLEUKIN 12 AND USE THEREOF IN PREPARING DRUGS FOR TREATING TUMOURS
    Publication number: 20220213161
    Abstract: The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent antitumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus.
    Type: Application
    Filed: March 22, 2022
    Publication date: July 7, 2022
    Inventors: Yaohe Wang, Pengju Wang, Lemoine Nick, Dongling GAO
  • Modified interleukin 12 and use thereof in preparing drugs for treating tumours
    Patent number: 11345732
    Abstract: The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent anti-tumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: May 31, 2022
    Assignees: BEIJING BIO-TARGETING THERAPEUTICS TECHNOLOGY INC., Zhengzhou University
    Inventors: Yaohe Wang, Pengju Wang, Lemoine Nick, Dongling Gao
  • Modified interleukin 12 and use thereof in preparing drugs for treating tumours
    Patent number: 11306129
    Abstract: The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent anti-tumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: April 19, 2022
    Assignees: BEIJING BIO-TARGETING THERAPEUTICS TECHNOLOGY INC., Zhengzhou University
    Inventors: Yaohe Wang, Pengju Wang, Lemoine Nick, Dongling Gao
  • MODIFIED INTERLEUKIN 12 AND USE THEREOF IN PREPARING DRUGS FOR TREATING TUMOURS
    Publication number: 20190010200
    Abstract: The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent antitumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus.
    Type: Application
    Filed: September 9, 2016
    Publication date: January 10, 2019
    Applicants: BEIJING BIO-TARGETING THERAPEUTICS TECHNOLOGY INC., Zhengzhou University
    Inventors: Yaohe Wang, Pengju Wang, Lemoine Nick, Dongling GAO